TVB-3567: a novel, broad spectrum antiviral targeting FASN

In preclinical studies, we have shown our FASN inhibitors:

• Reduce the replication of multiple viruses, including respiratory syncytial virus (RSV), parainfluenza virus 3 (PIV3), human rhinovirus (HRV), the severe adult respiratory syndrome virus (SARS) and hepatitis viruses
• Reduce the amount of virus in the lungs of mice infected with RSV virus and that this reduction in virus is associated with a reduction in inflammatory cells in the lungs of these animals
• Reduce the emergence of drug resistant virus compared to direct acting antivirals

Based on these data, our initial focus is on a broad spectrum anti-viral for respiratory infections. Respiratory viruses can cause severe infections in patients with cystic fibrosis, stem-cell transplant recipients, solid organ transplant patients, elderly patients, including those with underlying lung disease, and children and only limited therapies are currently available for a subset of these patients.

We are in preclinical studies with this product candidate.